Physician profile
John K Lambrix
NPI 1740576933
$602.46
in general payments reported to CMS, 2019-2025
11 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.00 · 2023: $330 · 2024: $113 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.64 | 2023-2024 | Farxiga, Breztri |
| Medtronic, INC. | $174.55 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $49.62 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $40.29 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $37.09 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.52 | 2024 | Givlaari |
| Pfizer INC. | $22.51 | 2023 | |
| Hikma Pharmaceuticals USA | $21.85 | 2023 | Kloxxado, Mitigare, Ryaltris |
| Dexcom, INC. | $20.01 | 2023 | Dexcom G6 Transmitter |
| Intuitive Surgical, INC. | $18.41 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lambrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.